Allogene Q2 FY26 net loss narrows to $42.68 million; revenue rises to $4.64 million

Reuters2026/08/12 20:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Allogene posted a Q2 2026 net loss of USD 42.7 million, narrowing from USD 50.94 million a year earlier.
Loss per share improved to USD 0.13 from USD 0.23 in Q2 2025.
Research and development spending fell to USD 30.72 million from USD 40.16 million year over year.
General and administrative costs climbed to USD 20.84 million from USD 14.28 million.
Cash, cash equivalents and investments rose to USD 423.6 million at June 30, projecting runway into 2029; 2026 operating expense seen near USD 165 million.
ALPHA3 interim futility review showed MRD negativity of 58.3% (7/12) on cema-cel versus 16.7% (2/12) on observation, a 41.6 percentage-point gap.
FDA granted RMAT and Fast Track designations for cema-cel as first-line consolidation in high-risk LBCL.
Site activation target moved up by six months, with about 100 sites expected active by year-end; next ALPHA3 update slated mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808096) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Allogene Q2 FY26 net loss narrows to $42.68 million; revenue rises to $4.64 million

You may also like

Crypto prices